

Please type a plus sign (+) inside this box.

04-18-01

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37C.F.R. §1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

APPLICATION ELEMENTS

Express Mail Label No. EM511114197US

Express Mail Label No. **EM511114197US**

1. *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- | | |
|---|--|
| 1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing) | 6. <input type="checkbox"/> Microfiche Computer Program (Appendix) |
| 2. <input checked="" type="checkbox"/> Specification [Total Pages 27] | 7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary) |
| <ul style="list-style-type: none"> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R&D - Reference in Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure | |
| 3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 11.3) [Total sheets 12] | 8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) |
| 4. <input checked="" type="checkbox"/> Oath or Declaration [Total pages 3] | 9. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement <input checked="" type="checkbox"/> Power of Attorney
(when there is an assignee) |
| <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 C.F.R. §§1.63(d)(2) and 1.33(b). | |
| 5. <input type="checkbox"/> Incorporation By Reference (useable if Box 1b is checked) | 10. <input type="checkbox"/> English Translation Document (if applicable) |
| <ul style="list-style-type: none"> 6. <input type="checkbox"/> Microfiche Computer Program (Appendix) 7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies | |
| ACCOMPANYING APPLICATION PARTS | |
| 11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations | |
| 12. <input checked="" type="checkbox"/> Preliminary Amendment | |
| 13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)
(Should be specifically itemized) | |
| 14. <input type="checkbox"/> *Small Entity <input type="checkbox"/> Statement filed in prior application
Statement(s) Status still proper and desired
(PTO/SB/09-12) | |
| 15. <input type="checkbox"/> Certified Copy of Priority Document(s)
(if foreign priority is claimed) | |
| 16. <input checked="" type="checkbox"/> Other: Priority Claim | |

Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

8. <input type="checkbox"/>	Assignment Papers (cover sheet & document(s))		
9. <input type="checkbox"/>	37 C.F.R. §3.73(b) Statement	<input checked="" type="checkbox"/>	Power of Attorney. <i>(when there is an assignee)</i>
10. <input type="checkbox"/>	English Translation Document <i>(if applicable)</i>		
11. <input type="checkbox"/>	Information Disclosure Statement (IDS)/PTO-1449	<input type="checkbox"/>	Copies of IDS Citations
12. <input checked="" type="checkbox"/>	Preliminary Amendment		
13. <input checked="" type="checkbox"/>	Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>		
14. <input type="checkbox"/>	*Small Entity Statement(s) <i>(PTO/SB/09-12)</i>	<input type="checkbox"/>	Statement filed in prior application, Status still proper and desired
15. <input type="checkbox"/>	Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>		
16. <input checked="" type="checkbox"/>	Other:	Priority Claim	
Priority claimed from US Provisional Application No. 60,200,040 filed April 27, 2000.			

***NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).**

17. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment:

Continuation Divisional Continuation-in-part (CIP) of prior application No. /

Prior application information: Examiner _____ **Group/Art Unit:** _____

18. CORRESPONDENCE ADDRESS

<input type="checkbox"/>	Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)	or <input checked="" type="checkbox"/>	Correspondence address below
Name	Paul H. Ginsburg			
Address	Pfizer Inc			
Address	235 East 42nd Street, 20th Floor			
City	New York	State	New York	Zip Code
Country	United States Of America	Telephone	(212)573-2369	Fax
NAME (Print/type)	Seth H. Jacobs		Registration No. (Attorney/Agent)	32,140
Signature			Date	April 17 th , 2001

USER:SYDOCSY, A218521\SHI\211401.DOC /165280 /Utility Trans PC10851A(SHI) [4/16/01]

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 1997.

Small Entity payments **must** be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$710.00)

METHOD OF PAYMENT (check one)

1. The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-1445

Deposit Account Name Pfizer Inc

- Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17. Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

2. Payment Enclosed:


Check Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Fee (\$)	Small Entity Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge – late fee or oath	
127	50	227	25	Surcharge – late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee (specify)					
Other Fee (specify)					
*Reduced by Basic Filing Fee Paid					
					SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

Type or Printed Name	Seth H. Jacobs			Complete (if Applicable)
Signature		Date	4/17/01	Reg. Number 32,140

CERTIFICATE OF MAILING EXPRESS MAIL

PFIZER DOCKET NO: PC10851A

APPLICATION NUMBER: NOT YET ASSIGNED

TITLE: ADAMTS POLYPEPTIDES, NUCLEIC ACIDS ENCODING THEM, AND USES THEREOF


APPLICANT: Leonard Buckbinder, *et al*

"Express Mail" mailing label number EM511114197US

Date of Deposit: April 17, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Vilma Pizarro



(Signature of person mailing paper or fee)

Pfizer, Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 573-2896